Janssen promises full focus on Darzalex after defeating Genmab in court

Although a ruling in Janssens favor comes as a slap in the face to its partner Genmab, the former has promised to continue to support bestseller drug Darzalex.
Photo: Piroschka Van De Wouw/Reuters/Ritzau Scanpix
Photo: Piroschka Van De Wouw/Reuters/Ritzau Scanpix
by benjamin werner christensen, translated by catherine brett

While Genmab remains tight-lipped about its defeat in court over a royalties dispute with partner Janssen, the latter has been a little more outspoken about the expected consequences of the ruling.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading